about
The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma.Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells.Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis
@ast
Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis
@en
Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis
@nl
type
label
Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis
@ast
Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis
@en
Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis
@nl
prefLabel
Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis
@ast
Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis
@en
Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis
@nl
P2093
P2860
P356
P1433
P1476
Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis
@en
P2093
Ashley A Kowalewski
R Lor Randall
Stephen L Lessnick
P2860
P304
P356
10.1155/2011/598704
P577
2010-11-01T00:00:00Z